If you’ve been told you have “bone-on-bone” knee arthritis, chances are the next sentence was something like: “You’re going to need a knee replacement eventually.” I hear this from patients regularly — and while that recommendation is sometimes appropriate, it’s also routinely made too early, too broadly, and without adequate consideration of what regenerative medicine can offer in the meantime.
Let me explain what bone-on-bone actually means, why it’s not a clean binary, and what options are realistically available before surgery. If you’re also weighing PRP against BMAC stem cell therapy for your knee, see my related post on PRP vs. BMAC for knee osteoarthritis.
What Does “Bone-on-Bone” Actually Mean?
The term bone-on-bone refers to severe narrowing of the joint space between the femur and tibia — typically visible on a standing X-ray as minimal or absent space between the two bones. It implies that most of the articular cartilage has been lost in the affected compartment.
What it doesn’t tell you is what’s actually driving your pain. And that distinction matters enormously.
Knee pain in osteoarthritis comes from multiple sources simultaneously: inflamed synovial tissue, damaged cartilage, stressed subchondral bone, bone marrow lesions, and sensitized nerve endings in the periosteum and joint capsule. An X-ray showing minimal joint space doesn’t tell you which of these is your primary pain generator — and different pain generators respond differently to different treatments.
The takeaway: bone-on-bone is a radiographic description, not a treatment plan.
Why the “Bone-on-Bone = Surgery” Equation Is Oversimplified
There is a fundamental mismatch between X-ray findings and patient symptoms that has been documented repeatedly in the research literature. Many patients with severe radiographic OA have moderate or minimal pain. Many patients with moderate radiographic changes have severe pain. The correlation between what the X-ray shows and how much a patient suffers is loose at best.
This matters because the decision to proceed with knee replacement surgery should be based primarily on functional limitation and quality of life — not X-ray grade alone. A patient with bone-on-bone findings who still walks comfortably, sleeps well, and maintains their lifestyle is not the same candidate as one who cannot complete basic daily activities despite optimal conservative care.
The Kellgren-Lawrence grading system classifies knee OA from Grade 0 (normal) to Grade 4 (severe). “Bone-on-bone” typically corresponds to Grade 4 — but even at Grade 4, the degree of pain, functional limitation, and treatment response varies enormously between patients. Grade alone does not determine candidacy for regenerative treatment.
The Hidden Driver Most Patients Never Hear About: Bone Marrow Lesions
One of the most important findings in knee osteoarthritis research — and one that most patients with bone-on-bone arthritis have never been told about — is the role of bone marrow lesions (BMLs) in driving pain and disease progression.
Bone marrow lesions are areas of microdamage, edema, and cellular stress within the subchondral bone — the dense bone layer just beneath the cartilage. They are only visible on MRI, not on X-ray. They are the single strongest MRI predictor of pain intensity in knee osteoarthritis — stronger than cartilage loss itself. They also predict the rate of cartilage loss over time.
A longitudinal analysis from the Osteoarthritis Initiative by Driban et al. confirmed that BML volume is significantly associated with both pain scores and joint space narrowing progression — meaning larger BMLs predict more pain and faster structural deterioration. (PMID: 24020939)
This matters for treatment because: standard intraarticular injections — cortisone, hyaluronic acid, even PRP delivered into the joint alone — do not reach the subchondral bone where BMLs occur. A treatment that doesn’t reach the lesion cannot meaningfully address it.
If your MRI report mentions “bone marrow edema,” “subchondral signal change,” or “bone marrow lesions” — and most advanced knee OA MRIs do — those findings deserve specific, targeted treatment. Bring your MRI to your consultation.
What Non-Surgical Options Exist?
Physical Therapy and Load Management
Strengthening the quadriceps, hamstrings, and hip abductors reduces mechanical load through the knee joint significantly. A structured physical therapy program should be the foundation of any non-surgical approach — not as a placeholder before surgery, but as an active intervention that can meaningfully reduce pain and improve function even in advanced OA.
PRP Therapy
For patients with significant cartilage loss who still have some joint space remaining, PRP therapy can reduce synovial inflammation and support the remaining cartilage environment. A 2024 meta-analysis of 35 randomized controlled trials found PRP superior to cortisone, hyaluronic acid, and saline at both mid-term and long-term follow-up. (PMID: 39222336) PRP is most effective in mild to moderate OA but can provide meaningful benefit in more advanced disease as well — particularly for the intraarticular inflammatory component.
BMAC Stem Cell Therapy — Including Intraosseous Injection
For patients with near bone-on-bone changes, BMAC bone marrow stem cell therapy represents the most potent non-surgical regenerative option available. BMAC delivers mesenchymal stem cells directly to the joint — cells that can modulate the inflammatory environment, support remaining tissue, and potentially slow the degenerative process at a cellular level that PRP alone cannot achieve.
What makes BMAC particularly relevant for bone-on-bone arthritis is the intraosseous delivery approach for bone marrow lesions. Research by Dr. Philippe Hernigou demonstrates that delivering BMAC directly into the subchondral bone — not just the joint space — produces dramatically superior outcomes. In his landmark 15-year randomized controlled trial, only 18% of knees treated with subchondral BMAC required knee replacement at 15 years — equivalent to the revision rate of the contralateral knee replacement performed in the same patients. Knees treated with intraarticular BMAC alone had a 70% conversion rate to total knee arthroplasty. The delivery site changes everything. (PMID: 32322943)
The Combined Approach: BMAC Plus Bone Marrow-Derived PRP
In practice, I almost always combine BMAC with PRP in a single treatment session — and importantly, the PRP I use is produced directly from the bone marrow aspirate itself, not from a separate blood draw. Processing the bone marrow aspirate yields both a cellular concentrate (BMAC) and a plasma fraction (bone marrow-derived PRP). This means we deliver mesenchymal stem cells, bone marrow growth factors, and bone marrow plasma simultaneously — addressing both the intraosseous and intraarticular environment in one procedure. This integrated approach is not available at practices using standard bedside centrifuge kits or off-the-shelf products.
Who Is a Realistic Candidate for Non-Surgical Treatment?
| Factor | Favorable for Regenerative Treatment | Less Favorable |
|---|---|---|
| Joint space | Some remaining, even if minimal | Complete destruction, severe deformity |
| Bone marrow lesions | Present — responds particularly well to intraosseous BMAC | Absent — still treatable but different target |
| Alignment | Relatively preserved | Severe valgus or varus deformity |
| Age/activity | Active adult seeking to delay or avoid surgery | Patient with multiple comorbidities limiting rehab |
| Prior treatment | Has not yet tried regenerative options | Has had multiple failed prior surgeries |
| Expectations | Meaningful pain relief and improved function | Restoration of a completely normal knee |
Patients with complete joint destruction, severe mechanical instability, or inflammatory arthritis requiring systemic management are better served by surgical consultation. The honest conversation is: I will tell you at your evaluation whether regenerative treatment is a realistic option for your specific imaging and clinical picture — not just whether it’s theoretically possible.
What the 15-Year Evidence Actually Shows
The most compelling evidence for non-surgical treatment in advanced knee OA comes from Dr. Hernigou’s randomized controlled trial — the only study in regenerative medicine with 15 years of follow-up in patients who were already scheduled for bilateral total knee replacement.
One knee received the planned replacement. The other received subchondral BMAC injection during the same anesthetic. At 15-year follow-up:
- 18% of the BMAC-treated knees required replacement — equivalent to the revision rate of the contralateral TKA
- 70% of knees treated with intraarticular BMAC alone required replacement — highlighting the importance of intraosseous delivery into the bone
- Bone marrow lesion regression after treatment was the single strongest predictor of which knees would avoid replacement long-term
This is not theoretical. These were patients deemed severe enough to need replacement on both knees simultaneously — and 82% of the BMAC-treated knees still hadn’t required replacement 15 years later. (PMID: 32322943)
Frequently Asked Questions
My orthopedic surgeon said I’m “not bad enough for surgery yet” — what does that mean for regenerative treatment?
This is one of the most frustrating positions for patients — told surgery isn’t appropriate yet, but not offered anything more meaningful than cortisone and waiting. This is exactly where regenerative medicine fills the gap. It’s a proactive biological intervention that may change the trajectory of the joint, not a lesser treatment for people who “don’t qualify” for surgery.
How do I know if I have bone marrow lesions?
BMLs are only visible on MRI. If your report mentions “bone marrow edema,” “subchondral signal change,” or “bone marrow lesion,” those findings are relevant to your treatment plan. Learn more about bone marrow lesions and targeted treatment.
Can BMAC be repeated if symptoms return?
Yes. Many patients experience improvement for 1–3 years. If symptoms return, the procedure can be repeated. Each treatment targets the active biological environment at that point — it does not foreclose future options including surgery if ultimately needed.
What is bone marrow-derived PRP and how is it different from regular PRP?
When bone marrow is aspirated for BMAC, the same sample is processed to also yield a PRP fraction — derived from bone marrow plasma rather than peripheral blood. Bone marrow plasma contains a distinct growth factor and cytokine profile that reflects the marrow environment, making it biologically different from blood-draw PRP. Delivering both components simultaneously means we address the joint at multiple biological levels from a single aspiration.
Does getting regenerative treatment now prevent me from having surgery later if I need it?
No. Choosing regenerative treatment first does not foreclose surgical options. Many patients use BMAC to buy years of meaningful function before surgery — at which point a knee replacement, if needed, is still available. The decision cannot be undone once made; trying conservative care first simply preserves optionality.
Is this covered by insurance?
BMAC and PRP are typically not covered by standard health insurance. Many patients find the investment meaningful when compared against the cost, risk, recovery time, and implant longevity concerns associated with total knee replacement surgery.
If you have been told you have bone-on-bone knee arthritis and want an honest assessment of whether regenerative treatment is a realistic option for your specific situation, schedule a consultation at our Miami clinic. I’ll review your imaging and give you a direct answer about what’s possible — not a blanket response based on grade alone.
Learn more: BMAC for knee osteoarthritis | PRP for knee osteoarthritis | Bone marrow lesions | Regenexx provider Miami | About Dr. Bonner
References
- Hernigou P, Delambre J, Quiennec S, Poignard A. Human bone marrow mesenchymal stem cell injection in subchondral lesions of knee osteoarthritis: a prospective randomized study versus contralateral arthroplasty at a mean fifteen year follow-up. Int Orthop. 2021;45(2):365-373. PMID: 32322943.
- Driban JB, Price L, Lo GH, et al. Evaluation of bone marrow lesion volume as a knee osteoarthritis biomarker — longitudinal relationships with pain and structural changes: data from the Osteoarthritis Initiative. Arthritis Res Ther. 2013;15(5):R112. PMID: 24020939.
- Bensa A, et al. Comparative effectiveness of intra-articular injections for knee osteoarthritis: a systematic review and meta-analysis of 35 randomized controlled trials. EFORT Open Rev. 2024. PMID: 39222336.
Disclaimer: This post is for educational purposes only and does not constitute medical advice. Results from regenerative treatments vary by individual, and not all patients are candidates. Please schedule a consultation to discuss your specific condition and treatment options.